PY
PolyPid Ltd.
PYPD · NASDAQ
$5.14 +0.49% (+$0.03)
1M +2.16%
Market Cap $96.0M
P/E Ratio -
Div. Yield -
ROE 311.08%
Bulios Fair Price
$2.63
48.8% downside
Current Price
$5.14
Undervalued Fair Value Overvalued
According to Bulios Fair Price, PYPD is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
1/9Valuation
0 /100
Expensive P/B 17.82x
P/E N/A
EV/EBITDA N/A
Growth
100 /100
Growing Book val. growth 23.47%
EPS growth N/A
Rev. growth N/A
Profitability
-
N/A Gross margin N/A
Net margin N/A
Op. margin N/A
Quality
26 /100
Poor ROIC 11.71%
ROE 311.08%
ROA 206.78%
Debt
60 /100
Moderate Debt/Equity 0.29x
Current ratio 1.35x
Int. coverage -1,314.00x
Stability
58 /100
Moderate Beta 1.42x
EPS volatility 8.24%
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about PYPD
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Dikla Czaczkes Akselbrad
Employees
72
Headquarters
Petah Tikva
Upcoming events
11 NOV
Earnings
Upcoming earnings report